NEW YORK, Jan 17 - Cambridge Antibody Technology on Thursday said it intends to acquire Canada's Drug Royalty Corp. for C$126 million, or roughly $78 million, worth of CAT stock.

The UK-based biotech company said it decided to snag Drug Royalty Corp. in order to help bolster its own therapeutic antibody portfolio it's building through collaborations with pharma and other biotech firms.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.